PHOQUS ANNOUNCES START OF CLINICAL STUDY ON CHRONOCORT

A A

Phoqus Group has begun its Phase I clinical trials program for Chronocort -- a Circadian endocrine treatment for adrenal insufficiency. Chronocort is a once-daily modified-release hydrocortisone tablet for the treatment of adrenal insufficiency, a condition which causes Addison's disease, hypopituitarism and congenital adrenal hyperplasia.

The initial Phase I trial, which will involve healthy volunteers dosed with the modified release hydrocortisone tablet formulation, is expected to be completed in early 2006. The objective is to evaluate the correlation between in-vitro hydrocortisone releases with the in-vivo blood levels observed following oral administration.